Want to see TMCI full AI Analyst Report?
TMCI Stock Chart & Stats
$4.00
$0.08(2.00%)
At close: 4:00 PM EDT
$4.00
$0.08(2.00%)
Day’s Range― - ―
52-Week Range$1.17 - $7.78
Previous Close$4.15
Volume237.57K
Average Volume (3M)918.48K
Market Cap
$282.25M
Enterprise Value$286.33
Total Cash (Recent Filing)$45.62M
Total Debt (Recent Filing)$72.69M
Price to Earnings (P/E)―
Beta2.51
Next Earnings
Nov 10, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding65,034,550
10 Day Avg. Volume1,009,218
30 Day Avg. Volume918,480
Financial Highlights & Ratios
PEG Ratio-0.79
Price to Book (P/B)1.77
Price to Sales (P/S)0.73
P/FCF Ratio-5.26
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.50Price Target Upside37.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.85
Revenue Forecast (FY)$207.48M
Bulls Say, Bears Say
Bulls Say
High Gross Margins And Strong Product EconomicsSustained gross margins near 80% indicate attractive economics for Lapiplasty and related devices. This provides a foundation for future operating leverage if Treace can scale procedures and control commercial and product costs.
Improving Leverage And Cash DisciplineLower debt reduces balance-sheet pressure and improves financial flexibility. The sharp reduction in cash usage also suggests cost actions are beginning to improve resource efficiency, extending the company’s capacity to fund commercialization.
Growing Surgeon Adoption And Broader Product PortfolioExpanding surgeon adoption supports recurring procedure-based demand and strengthens Treace’s commercial reach. New products across forefoot, midfoot and hindfoot procedures can increase wallet share and expand the addressable market over time.
Bears Say
Persistent Losses And Negative Cash GenerationTreace has not yet converted strong gross margins into profitability or positive cash generation. Continued operating losses and cash consumption could constrain investment, increase financing dependence and weaken flexibility if growth remains subdued.
Revenue Slowdown And Unfavorable Product MixRevenue weakness and mix-related ASP pressure challenge the company’s ability to scale fixed costs. If lower-priced procedures remain a larger share of demand, growth may not translate into sufficient revenue or profit improvement.
Competitive And Commercialization Execution RiskTreace’s growth strategy depends on differentiating products and converting launches into sustained surgeon usage. Larger rivals could replicate innovations, while weaker adoption or rollout delays would prolong revenue pressure and operating losses.
Treace Medical Concepts News
TMCI FAQ
What was Treace Medical Concepts’s price range in the past 12 months?
Treace Medical Concepts lowest stock price was $1.17 and its highest was $7.78 in the past 12 months.
What is Treace Medical Concepts’s market cap?
Treace Medical Concepts’s market cap is $282.25M.
When is Treace Medical Concepts’s upcoming earnings report date?
Treace Medical Concepts’s upcoming earnings report date is Nov 10, 2026 which is in 77 days.
How were Treace Medical Concepts’s earnings last quarter?
Treace Medical Concepts released its earnings results on Aug 07, 2026. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.298 by $0.058.
Is Treace Medical Concepts overvalued?
According to Wall Street analysts Treace Medical Concepts’s price is currently Undervalued.
Does Treace Medical Concepts pay dividends?
Treace Medical Concepts does not currently pay dividends.
What is Treace Medical Concepts’s EPS estimate?
Treace Medical Concepts’s EPS estimate is -0.25.
How many shares outstanding does Treace Medical Concepts have?
Treace Medical Concepts has 65,034,550 shares outstanding.
What happened to Treace Medical Concepts’s price movement after its last earnings report?
Treace Medical Concepts reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.298. Following the earnings report the stock price went up 8.676%.
Which hedge fund is a major shareholder of Treace Medical Concepts?
Currently, no hedge funds are holding shares in TMCI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Treace Medical Concepts Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.50 (37.50% Upside)
$5.50 (37.50% Upside)
Hedge Fund Trend
Decreased
By 1.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $974.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.80%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-12.30%
Trailing 12-Months
Company Description
Treace Medical Concepts
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percuplasty Percutaneous 3D Bunion Correction System that provides 3D correction of the bunion deformity through percutaneous incisions. It also provides Adductoplasty System, a system designed for the correction of metatarsus adductus deformities and osteoarthritis of the midfoot; SpeedMTP Rapid Compression Implant; SpeedPlate Implant Fixation Platform to address the fusion of larger bones of the midfoot and rearfoot; SpeedPlate Micro-Quad implant, an implant designed for stability and fit in small incision surgical approaches; and SpeedAkin Anatomic Compression Implant. In addition, the company offers The IntelliGuide patient specific instrumentation provides patient-specific, 3D-printed cut guides, and a pre-operative plan for a complete picture of the deformity and correction. Further, it provides FastGrafter Autografter Harvesting System; SpeedRelease Guided Release Instrument; TriTome Triple-Edge Release Instrument; RazorTome 7mm Precision Osteotome; LapiTome Hooked Bone Removal Osteotome; GreatRelease Rapid MTP Release Instrument; CornerChisel Release Tool; NanoRasp MIS Bone Contouring Tool; FeatherRasp Rapid Bone Contouring Instrument; and Akinator Single-cut Akin Wedge Osteotomy tool. Additionally, the company offers biologics and wedges, such as Treace Allograft Wedges; and CortiFuse Flowable Cortical Fibers. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.
TMCI Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call is cautiously positive. Management reported accelerating case volumes, improving surgeon adoption of new products, tightened operating expenses (–8%), improved adjusted EBITDA and a large pipeline of product launches and TAM expansion. They raised full‑year revenue guidance modestly and materially reduced YTD cash usage (–57%). However, top-line pressure persists (Q2 revenue down 4% and full‑year guidance still implies a decline of up to 4%), gross margin compressed slightly, and the company remains EBITDA‑negative for the year, relying on a seasonal Q4 and successful execution of new product rollouts to return to growth. Balancing the clear commercial momentum and improved profitability metrics against ongoing mix headwinds, negative adjusted EBITDA guidance for the year, and execution/competitive risks, the positives outweigh the negatives but warrant cautious monitoring.View all TMCI earnings summariesTMCI Stock 12 Month Forecast
Average Price Target
$5.50
▲(37.50% Upside)
Technical Analysis
Ownership Overview
27.82% Insiders
6.07% Mutual Funds
19.32% Other Institutional Investors
41.82% Public Companies and
Individual Investors